Federal Register Notice: FDA is making available final product-specific bioequivalence (BE) recommendations that provide guidance on the design of BE studies to support ANDAs. Products include cephalexin, ciprofloxacin, glimepiride, and imatinib mesylate. To view this notice, click here.
